Alfonso Muriel Garcia
Overview
Explore the profile of Alfonso Muriel Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
25
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Jorge F, Fernandez-Velasco J, Villarrubia N, Gracia-Gil J, Fernandez E, Meca-Lallana V, et al.
Front Immunol
. 2025 Jan;
15:1535051.
PMID: 39749346
[This corrects the article DOI: 10.3389/fimmu.2024.1480676.].
2.
Artiles Medina A, Subiela Henriquez J, Muriel Garcia A, Minguez Ojeda C, Sanchez Gonzalez A, De La Parra Sanchez I, et al.
Minerva Urol Nephrol
. 2024 Dec;
PMID: 39625639
No abstract available.
3.
Rodriguez-Jorge F, Fernandez-Velasco J, Villarrubia N, Gracia-Gil J, Fernandez E, Meca-Lallana V, et al.
Front Immunol
. 2024 Nov;
15:1480676.
PMID: 39606235
Objective: To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing-remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association...
4.
Artiles Medina A, Minguez Ojeda C, Subiela Henriquez J, Muriel Garcia A, Sanchez Gonzalez A, Mata Alcaraz M, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102205.
PMID: 39278152
Introduction: Our objectives were to analyse the incidence of changes in renal function after radical cystectomy (RC) and determine the factors responsible for those changes, as a basis for rethinking...
5.
Carton Erlandsson L, Martin Duce A, Gragera Martinez R, Sanz Guijo M, Muriel Garcia A, Miron Gonzalez R, et al.
Rev Esp Salud Publica
. 2024 May;
98.
PMID: 38738501
Objective: Social media allows individuals to access a vast amount of health-related information immediately and anonymously, a fact that is turning these platforms into one of the primary sources of...
6.
Escudero-Sanchez R, Ramos-Martinez A, Caballero-Bermejo A, Diaz-Pollan B, Ruiz-Carrascoso G, Samperio M, et al.
Eur J Clin Microbiol Infect Dis
. 2024 Jan;
43(3):533-540.
PMID: 38236366
Purpose: To describe a cohort with a high risk of recurrence who received bezlotoxumab during the first episode of Clostridioides difficile infection (CDI) and to compare this cohort with patients...
7.
Vizcarra P, Moreno A, Vivancos M, Muriel Garcia A, Ramirez Schacke M, Gonzalez-Garcia J, et al.
J Bone Miner Res
. 2023 Aug;
38(10):1443-1452.
PMID: 37545089
People with HIV have a higher risk of fracture than the general population. Because of the low performance of the existing prediction tools, there is controversy surrounding fracture risk estimation...
8.
Burgos Revilla F, Artiles Medina A, Dominguez Gutierrez A, Muriel Garcia A, Figueiredo A, Gomez Dos Santos V
BJU Int
. 2023 Apr;
132(3):239-251.
PMID: 37017627
Objective: To assess the safety of vascular closure devices in living-donor nephrectomy (LDN), as staplers and non-transfixion techniques (polymer locking and metal clips) are the methods employed to secure the...
9.
Vizcarra P, Moreno A, Vivancos M, Muriel Garcia A, Gonzalez R, Gutierrez F, et al.
AIDS Patient Care STDS
. 2022 Dec;
37(1):11-21.
PMID: 36576916
Current guidelines recommend screening people with HIV (PWH) for bone disease using predictive tools developed for the general population, although data on PWH are scarce. In this study, we assessed...
10.
Escudero-Sanchez R, Muriel Garcia A, Garcia Fernandez S, Valencia Alijo A, Tasias Pitarch M, Merino de Lucas E, et al.
J Antimicrob Chemother
. 2022 Apr;
77(7):1996-2002.
PMID: 35403189
Background: Both fidaxomicin and bezlotoxumab (used in combination with an antibiotic against Clostridioides difficile) achieve reductions in recurrence rates of C. difficile infection (CDI). However, the two strategies have never...